Primary central nervous system lymphoma in daily practice and the role of autologous stem cell transplantation in relapsed disease: A retrospective multicenter study
No Thumbnail Available
Date
2016
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
We investigated the course of 54 patients presenting with primary central nervous system lymphoma, who were treated in daily practice. The patients were treated with chemotherapy and/or radiotherapy and/or intrathecal chemotherapy. At a median follow-up period of 23 months (range 1-71), median relapse-free survival (RFS) and overall survival (OS) were not reached. Estimated 2-year RFS and OS rates were 42% and 48%, respectively. Ten relapsed PCNSL patients underwent ASCT. Complete remission rate of these patients was 40%, with 20% treatment-related mortality. Estimated 2-year RFS and OS rates were 37% and 40%, respectively. The prognosis of patients with PCNSL, who received off-study treatment, is still dismal. © 2016 Elsevier Ltd.
Description
Keywords
Aged , Aged, 80 and over , Central Nervous System Neoplasms , Demography , Humans , Lymphoma , Middle Aged , Practice Patterns, Physicians' , Recurrence , Retrospective Studies , Stem Cell Transplantation , Transplantation, Autologous , Young Adult , busulfan , cyclophosphamide , cytarabine , etoposide , melphalan , thiotepa , adult , aged , Article , autologous stem cell transplantation , cancer chemotherapy , cancer prognosis , cancer radiotherapy , female , follow up , general practice , human , major clinical study , male , medical record review , mortality , multicenter study , overall survival , primary central nervous system lymphoma , recurrence free survival , relapse , remission , retrospective study , very elderly , autotransplantation , Central Nervous System Neoplasms , clinical practice , clinical trial , demography , lymphoma , middle aged , recurrent disease , stem cell transplantation , young adult